RA

Hidden Costs Of Arthritis Treatment Include Liver Damage, Medical Bills, And Serious Impacts Highlight Role of SSDI Benefits, Allsup Reports

Retrieved on: 
Tuesday, August 29, 2023

A recent study , “Research on Liver Damage Caused by the Treatment of Rheumatoid Arthritis with Novel Biological Agents or Targeted Agents,” highlights the double-edged sword of RA treatments.

Key Points: 
  • A recent study , “Research on Liver Damage Caused by the Treatment of Rheumatoid Arthritis with Novel Biological Agents or Targeted Agents,” highlights the double-edged sword of RA treatments.
  • The study emphasized the importance of regular liver function tests for patients undergoing these treatments, suggesting that early detection of liver anomalies can lead to timely intervention and prevent severe complications.
  • “When filing your Social Security disability claim, it’s important to tell the story of your experience with a health condition like rheumatoid arthritis, which can include the health impacts of the treatment,” said T.J. Geist, Principal Advocate at Allsup.
  • When considering filing for SSDI benefits, it’s vital to have medical support and documentation of your condition.

COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors

Retrieved on: 
Wednesday, August 16, 2023

Each Warrant will have an exercise price of $9.93 per ADS, representing a 30% premium to the last sale price.

Key Points: 
  • Each Warrant will have an exercise price of $9.93 per ADS, representing a 30% premium to the last sale price.
  • The financing is expected to close on August 18, 2023, subject to customary closing conditions.
  • Kabir Nath, Chief Executive Officer of COMPASS Pathways, said, “We are grateful for the support of this group of leading healthcare investors for our work to bring potentially transformative treatment for mental health conditions to patients urgently in need of better options.
  • Morgan Stanley and TD Cowen are acting as the placement agents for the private placement.

Gracell Biotechnologies Reports Second Quarter 2023 Unaudited Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 14, 2023

ET today

Key Points: 
  • ET today
    SAN DIEGO and SUZHOU, China and SHANGHAI, China, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today reported second quarter unaudited financial results for the period ended June 30, 2023, and provided corporate updates.
  • “We are delighted with the significant milestones achieved in the past few months across our reprioritized pipeline.
  • The Phase 1b part of the RRMM US IND trial has commenced as patient screening is underway.
  • Financial Results for Second Quarter Ended June 30, 2023
    As of June 30, 2023, the Company had RMB1,188.0 million (US$163.8 million) in cash and cash equivalents and short-term investments.

FDA Accepts MyMD Pharmaceuticals’ Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA)

Retrieved on: 
Monday, August 14, 2023

MYMD-1 is an oral, next-generation TNF-α inhibitor with the potential to transform the way TNF-α based diseases are treated due to its selectivity and ability to cross the blood brain barrier.

Key Points: 
  • MYMD-1 is an oral, next-generation TNF-α inhibitor with the potential to transform the way TNF-α based diseases are treated due to its selectivity and ability to cross the blood brain barrier.
  • Its ease of oral dosing is a significant differentiator compared to currently available TNF-α inhibitors, all of which require delivery by injection or infusion.
  • MYMD-1 has also been shown to selectively block TNF-α action where it is overactivated without preventing it from doing its normal job of responding to routine infection.
  • In addition, in early clinical studies it has not been associated with serious side effects known to occur with traditional immunosuppressive therapies that treat inflammation.

Novel biologic Ab-IPL-IL-17™ shows promise for rheumatoid arthritis and inflammatory bowel disease

Retrieved on: 
Tuesday, August 15, 2023

The antibody, called Ab-IPL-IL-17™, targets a specific section of signalling proteins IL-17A and IL-17F which play a central role in sustaining inflammation during onset and progression of autoimmune diseases.

Key Points: 
  • The antibody, called Ab-IPL-IL-17™, targets a specific section of signalling proteins IL-17A and IL-17F which play a central role in sustaining inflammation during onset and progression of autoimmune diseases.
  • A patent application has been filed covering the antibody and its therapeutic use.
  • The researchers are seeking commercial partners willing to conduct a large-scale clinical evaluation of Ab-IPL-IL17™ in patients with immune-mediated inflammatory diseases (IMIDs).
  • For commercial enquiries contact Dr Veemal Bhowruth at University of Birmingham Enterprise.

Novel biologic Ab-IPL-IL-17™ shows promise for rheumatoid arthritis and inflammatory bowel disease

Retrieved on: 
Tuesday, August 15, 2023

The antibody, called Ab-IPL-IL-17™, targets a specific section of signalling proteins IL-17A and IL-17F which play a central role in sustaining inflammation during onset and progression of autoimmune diseases.

Key Points: 
  • The antibody, called Ab-IPL-IL-17™, targets a specific section of signalling proteins IL-17A and IL-17F which play a central role in sustaining inflammation during onset and progression of autoimmune diseases.
  • A patent application has been filed covering the antibody and its therapeutic use.
  • The researchers are seeking commercial partners willing to conduct a large-scale clinical evaluation of Ab-IPL-IL17™ in patients with immune-mediated inflammatory diseases (IMIDs).
  • For commercial enquiries contact Dr Veemal Bhowruth at University of Birmingham Enterprise.

NexImmune Reports Second Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, August 10, 2023

We believe that the ability to bypass the host dendritic cell and directly engage T cells in the body provides the potential for greater specific T cell responses.

Key Points: 
  • We believe that the ability to bypass the host dendritic cell and directly engage T cells in the body provides the potential for greater specific T cell responses.
  • Cash and cash equivalents for the Company as of June 30, 2023 were $16.3 million compared to $34.6 million at December 31, 2022.
  • Based upon current operating plans, NexImmune expects that its existing cash and cash equivalents will enable the Company to fund its operating and capital expenditure requirements into the fourth quarter of 2023.
  • Research and development expenses were $4.9 million in the second quarter of 2023, compared to $11.8 million for the same period in the prior year.

Auriemma Roundtables Acquires insideARM

Retrieved on: 
Wednesday, August 9, 2023

Auriemma Roundtables , a leading business intelligence provider for the consumer finance ecosystem, is excited to announce the acquisition of insideARM, LLC, including the insideARM and Collections & Recovery media brands, and the Consumer Relations Consortium (CRC) and Research Assistant (RA) membership groups.

Key Points: 
  • Auriemma Roundtables , a leading business intelligence provider for the consumer finance ecosystem, is excited to announce the acquisition of insideARM, LLC, including the insideARM and Collections & Recovery media brands, and the Consumer Relations Consortium (CRC) and Research Assistant (RA) membership groups.
  • The insideARM, LLC acquisition will further expand Auriemma Roundtables’ presence in Collections to provide additional value for third-party accounts receivable management executives.
  • “insideARM and its product suite is well-respected and will help strengthen our presence in the Collections and Risk space,” said Tom LaMagna, President of Auriemma Roundtables.
  • “This solidifies our continued commitment to build our presence as the core source for data and knowledge in financial services.”
    “Auriemma Roundtables shares the insideARM brand values and has the roadmap and capabilities to take our initiatives to the next level,” said Eidelman, insideARM founder.

XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial

Retrieved on: 
Tuesday, August 8, 2023

AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today began treating the first patient in a phase II, double-blind, placebo-controlled, randomized clinical study to evaluate Natrunix as a new treatment for Arthritis.

Key Points: 
  • AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today began treating the first patient in a phase II, double-blind, placebo-controlled, randomized clinical study to evaluate Natrunix as a new treatment for Arthritis.
  • Natrunix blocks a key cause of inflammation involved in pain and joint destruction in rheumatoid arthritis (RA).
  • The primary endpoint of the Phase II is the American College of Rheumatology (ACR) 20% Response (ACR 20) rate at 12 weeks.
  • In addition, it is expected that 300,000 children will suffer from juvenile arthritis (Arthritis Foundation, 2023).

Applied BioMath, LLC Awarded Grant by the National Institutes of Health for a Simulation Platform to Predict Dose and Therapeutic Window of Immunocytokines

Retrieved on: 
Tuesday, August 8, 2023

Immunocytokines (ICs) are a promising class of cytokine-based therapeutics with potential applications in diseases such as rheumatoid arthritis (RA), psoriasis, and cancer.

Key Points: 
  • Immunocytokines (ICs) are a promising class of cytokine-based therapeutics with potential applications in diseases such as rheumatoid arthritis (RA), psoriasis, and cancer.
  • However, achieving an adequate therapeutic window is complicated because of the potentially high risk of toxicity due to off-target effects.
  • The grant referenced in this press release is supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R44AI177133.
  • The content is solely the responsibility of Applied BioMath, LLC and does not necessarily represent the official views of the National Institutes of Health.